VIP
GILD icon

Vantage Investment Partners’s Gilead Sciences GILD Stock Holding History

Vantage Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-147,559
Closed -$10.4M – 71
2017
Q2 		$10.4M Buy
147,559
+559
+0.4% +$37.2K 0.95% 37
2017
Q1 		$9.98M Buy
+147,000
New +$10.3M 1.11% 33
2016
Q4 		– Sell
-130,008
Closed -$10.3M – 62
2016
Q3 		$10.3M Buy
130,008
+3,699
+3% +$300K 1.33% 27
2016
Q2 		$10.5M Buy
126,309
+40,600
+47% +$3.6M 1.1% 36
2016
Q1 		$7.87M Buy
85,709
+56,459
+193% +$5.09M 0.93% 33
2015
Q4 		$2.96M Buy
+29,250
New +$3.04M 0.47% 46

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vantage Investment Partners's GILD Position: Q3 2017 in Review

Vantage Investment Partners sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 147,559 shares — an estimated $10.4M sold.

Vantage Investment Partners first reported a position in GILD in Q4 2015 and held it in 6 quarters. The position peaked at $10.5M in Q2 2016. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Vantage Investment Partners reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Vantage Investment Partners sold 147,559 Gilead Sciences shares in Q3 2017, an estimated $10.4M.
  • Vantage Investment Partners first reported a position in Gilead Sciences in Q4 2015 and held it in 6 quarters.
  • Vantage Investment Partners's Gilead Sciences position peaked at $10.5M in Q2 2016.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Vantage Investment Partners's 13F filing for Q3 2017, filed 14 Nov 2017.